Status:
COMPLETED
Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Rhinitis, Allergic, Seasonal
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to assess the safety and tolerability of MK-3641 (short ragweed \[Ambrosia artemisiifolia\] extract, SCH 039641, RAGWITEK®) sublingual tablets and MK-7243 (Timothy grass \...
Detailed Description
Events of local swelling include pharyngeal edema, laryngeal edema, mouth edema, oropharyngeal swelling, palatal edema, tongue swelling/edema or throat tightness.
Eligibility Criteria
Inclusion
- Clinical history of physician-diagnosed ragweed- and grass pollen-induced rhinitis with or without conjunctivitis of \>1 year duration, with or without asthma
- Female participants of childbearing potential must have a negative urine pregnancy test at Screening and Randomization Visits and must agree to remain abstinent or use (or have their partner use) any one of the acceptable methods of birth control within the projected duration of the study. Acceptable methods of birth control are: intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, condom, vasectomy, hormonal contraception.
Exclusion
- Unstable, uncontrolled or severe asthma treated with long-acting beta agonists (LABAs) at the time of Screening
- Received immunosuppressive treatment within 3 months prior to Randomization (except steroids for allergic reactions other than asthma)
- History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, unknown cause, or inhalant allergen
- Diagnosis of eosinophilic esophagitis
- History of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy
- Female and breastfeeding, pregnant or intending to become pregnant
- Received another form of allergen immunotherapy with the past month
- Previously exposed to MK-3641 (RAGWITEK®) or other sublingual ragweed immunotherapy
- Previously exposed to MK-7243 (GRASTEK®) or other sublingual grass immunotherapy
- Known history of allergy, hypersensitivity, or intolerance to the excipient ingredients of the study drug (except for Ambrosia artemisiifolia and/or Phleum pratense), or self-injectable epinephrine
- Unable to or will not comply with the use of self-injectable epinephrine
- Used an investigational drug within 30 days prior to Screening Visit, or plans to participate in another interventional clinical trial during the duration of this trial
- Family member of the investigational or sponsor staff involved in this trial
- Participating in this same trial at another investigational site.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2015
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT02256553
Start Date
October 1 2014
End Date
February 1 2015
Last Update
March 3 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.